Caladrius Biosciences is a clinical-stage biopharmaceutical company focused on the development of treatments and reversal of severe diseases. Co.'s product candidates include: XOWNA®, which is a Phase 2a study and an ongoing follow-on Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction; HONEDRA®, which is eligible for early conditional approval in Japan for the treatment of critical limb ischemia based on the results of a clinical trial; and CLBS201, which is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes.
|
Free CLBS Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |